Please find enclosed the Newspaper Publication in Business Standard and Andhra Prabha for the un-audited Financial Results for the quarter ended june 30, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Godavari Drugs Ltd has submitted copies of newspaper advertisements of its un-audited standalone and consolidated financial results for the quarter ended June 30, 2025 (Q1 FY26), published in Business Standard (English, all editions) and Andhra Prabha (Telugu, Hyderabad edition) on August 14, 2025. From the published numbers, standalone total income from operations fell to Rs. 2,382.35 lakhs in Q1 FY26 from Rs. 3,297.28 lakhs in Q1 FY25, a decline of about 28% year-on-year. Net profit after tax dropped to Rs. 104.06 lakhs from Rs. 163.08 lakhs over the same period, down roughly 36% YoY. Sequentially, however, profit after tax improved from Rs. 89.31 lakhs in Q4 FY25 to Rs. 104.06 lakhs in Q1 FY26. Equity share capital stood at Rs. 3,581.56 lakhs. Basic and diluted EPS for Q1 FY26 was Rs. 1.38 each.
The filing itself is a routine compliance submission of already-disclosed quarterly results, so no fresh announcement effect is expected. The underlying numbers, however, point to a weak year-on-year performance with both top line and bottom line shrinking, which may weigh on near-term sentiment even as the sequential uptick in profit offers some cushion.